Extranodal NK/T Cell Lymphoma, Nasal Type

Suzuki, Ritsuro

doi:10.1007/978-3-319-18257-5_21

Cited by 5 publications

(6 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T‐cell lymphoma is a subtype of non‐Hodgkin's lymphoma, with a significantly higher incidence in Asia and Latin America than in Europe and the United States . The pathological features of T‐LBL are vascular central infiltration and destruction, often accompanied by obvious tissue necrosis, highly invasive probability, insensitive to chemotherapy and poor prognosis .…”

Section: Discussionmentioning

confidence: 99%

MEG3 affects the progression and chemoresistance of T‐cell lymphoblastic lymphoma by suppressing epithelial‐mesenchymal transition via the PI3K/mTOR pathway

Deng

Fan

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNA) are emerging as integral functional and regulatory components in the development of different diseases including cancer. Maternally expressed gene 3 (MEG3), is a lncRNA, that has a depressed expression in multiple tumor types, including T‐cell lymphoblastic lymphoma (T‐LBL). However, the molecular mechanisms that regulate the tumorigenic functions of MEG3 in T‐LBL remain largely unknown. In this study, we aimed to discover and identify the function of MEG3 in T‐LBL tumorigenesis, epithelial‐mesenchymal transition (EMT) and drug resistance, and explore their mechanisms of action. Knockdown MEG3 promoted the proliferation, migration, invasion, and drug resistance of T‐LBL cells while overexpression of MEG3 gets the opposite results. The mechanism study showed that decreased MEG3 expression in T‐LBL cells could activate PI3K/mTOR signaling pathways, increase the expression of p‐glycoprotein and affect the expression of EMT markers for transforming to mesenchymal cells in vitro and in vivo. Together, these results indicate that MEG3 could inhibit the migration, invasion, and drug resistance in T‐LBL cells by suppression of the PI3K/mTOR pathway. MEG3 might be a potential target, through which poor prognosis with high recurrence and drug resistance of T‐LBL in a clinical setting could be reversed.

show abstract

Section: Discussionmentioning

confidence: 99%

MEG3 affects the progression and chemoresistance of T‐cell lymphoblastic lymphoma by suppressing epithelial‐mesenchymal transition via the PI3K/mTOR pathway

Deng

Fan

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…In the current study, 60.7% of the 56 patients with ENKTCL expressed EBER, which is consistent with the previous report. Studies by Suzuki et al 22 and Wang et al 23 demonstrated that the EBV DNA copy number in the peripheral blood of patients is a good indicator of the tumor load and therefore, could be used to predict the tumor response and potential adverse reactions to chemotherapy in ENKTCL. However, the current study showed that EBER had no significant effect on prognosis.…”

Section: Discussionmentioning

confidence: 99%

Correlation between the clinicopathological features and prognosis in patients with extranodal natural killer/T cell lymphoma

Zeng

Huang

Qiu

et al. 2017

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

ObjectiveTo investigate the correlation between the clinicopathological features and prognosis in patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTCL).MethodsOne hundred and four patients diagnosed with ENKTCL at the Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China from November 1991 to September 2011 were included in the study. The clinicopathological features and their correlations with disease prognosis were evaluated in these patients.ResultsThe number of effective follow-up cases was 56 (53.8%) by the end of last follow-up in October 2015. Univariate survival analysis showed that granzyme B, perforin, and Bcl-2 expression was significantly associated with a poor prognosis in ENKTCL (P = 0.033, 0.004, and 0.034, respectively), whereas platelet-derived growth factor receptor-alpha (PDGFRA) expression was significantly associated with a better prognosis (P = 0.034). Ki-67 overexpression (≥50%) was significantly associated with a poor prognosis (P = 0.017). Different treatment approaches were also associated with prognosis (P = 0.014); specifically, the efficacies of combination treatments including chemotherapy and radiotherapy, and autologous hematopoietic stem cell transplantation were significantly better than those involving radiotherapy and chemotherapy alone. Patient gender, age, tumor location, staging, the presence of B symptoms, pretreatment lactate dehydrogenase levels, and β2-microglobulin levels were not associated with the prognosis of ENKTCL (P > 0.05). However, multivariate analyses showed that the treatment approach and all the immune markers were not independent prognostic factors for ENKTCL.ConclusionGranzyme B, perforin, and Bcl-2 expression and Ki-67 overexpression (≥50%) might be adverse prognostic factors for ENKTCL, whereas PDGFRA-positivity suggested a better disease prognosis. In addition, different treatment approaches might be closely related to patient prognosis.

show abstract

“…It is a non-Hodgkin's lymphoma (NHL) that is rare in Western Countries but common in East Asia and Latin America. While lymphoma genesis specific for NK/T cell lymphoma is largely unknown, the Epstein-Barr virus (EBV) has been detected in almost all ENKLs [7]. EBV has a transforming activity on lymphocytes and may play an important role in lymphoma genesis.…”

Section: Pathologic Findingsmentioning

confidence: 99%

“…Histological specimens of ENKL have been shown to have diffuse proliferation of lymphoma cells with an angiocentric or angiodestructive growth pattern. The lymphoma cell express NK cell markers including CD2, cytoplasmic CD3, CD7 and CD56 [7,8].…”

Section: Pathologic Findingsmentioning

confidence: 99%

See 1 more Smart Citation

Extranodal T- NK-cell lymphoma, nasal type masquerading as ileal inflammatory bowel disease

Okoji¹,

Mannan²,

Holt³

et al. 2015

IJCRI

View full text Add to dashboard Cite

Extranodal NK/T Cell Lymphoma, Nasal Type

Cited by 5 publications

References 64 publications

MEG3 affects the progression and chemoresistance of T‐cell lymphoblastic lymphoma by suppressing epithelial‐mesenchymal transition via the PI3K/mTOR pathway

MEG3 affects the progression and chemoresistance of T‐cell lymphoblastic lymphoma by suppressing epithelial‐mesenchymal transition via the PI3K/mTOR pathway

Correlation between the clinicopathological features and prognosis in patients with extranodal natural killer/T cell lymphoma

Extranodal T- NK-cell lymphoma, nasal type masquerading as ileal inflammatory bowel disease

Contact Info

Product

Resources

About